Development of carrier-free nanodrugs based on low molecular weight heparin–doxorubicin conjugate assembly with smart pH-triggered drug release characteristics for combinatorial antitumor therapy

Abstract

A LMWH–DOX nanodrug effectively released bioactive agents, providing a combination therapy of low molecular weight heparin and doxorubicin for angiogenesis suppression and carcinoma inhibition.